TIXiMED
Manufacturing · Alabama, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1927 1st Ave N, Birmingham, Alabama, 352...Website
www.tiximed.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About TIXiMED
TIXiMED develops and commercializes TXNIP [tix-nip] inhibiting medication as a first-of-its-kind oral therapeutic for Type 1 and Type 2 Diabetes.Explore more
TIXiMED Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is TIXiMED your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
TIXiMED, which may be a good buyer, showed buying intent in Masked Content Topic
Check if TIXiMED has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at TIXiMED
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if TIXiMED is spiking on competitors!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once TIXiMED has new funding data
Product Launch: Get notified when TIXiMED launches new products
Click to see if TIXiMED had a recent Job posting/layoffs
Earning: See what the market has to say on TIXiMED recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined TIXiMED as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
TIXiMED is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
TIXiMED is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about TIXiMED.
TIXiMED financials insights
Gather financial insights about TIXiMED, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Debt
$2.6M
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Event
Events
Event
TIXiMED News & Media
TIXiMED Inc. Announces Successful Dosing of First Cohort in the Phase 1 Clinical Trial of TIX100, its Investigational Disease-Modifying Treatment for Type 1 Diabetes
BIRMINGHAM, Ala.--(BUSINESS WIRE)--TIXiMED Inc. (www.tiximed.com), a clinical-stage pharmaceutical company based on the breakthrough discovery that TXNIP plays an important role in the development and progression of diabetes, today announced successful dosing of the first dose cohort in the Phase 1 Single Ascending Dose (SAD) trial of TIX100, its investigational novel oral therapy targeting beta cell health and islet cell function. Additionally, based on the safety review meeting, it was recommTIXiMED Inc. Announces Successful Dosing of First Cohort in the Phase 1 Clinical Trial of TIX100, its Investigational Disease-Modifying Treatment for Type 1 Diabetes
BIRMINGHAM, Ala.--(BUSINESS WIRE)--TIXiMED Inc. (www.tiximed.com), a clinical-stage pharmaceutical company based on the breakthrough discovery that TXNIP plays an important role in the development and progression of diabetes, today announced successful dosing of the first dose cohort in the Phase 1 Single Ascending Dose (SAD) trial of TIX100, its investigational novel oral therapy targeting beta cell health and islet cell function. Additionally, based on the safety review meeting, it was recommTIXiMED Announces a $2.65M Program-Related Investment from the Helmsley Charitable Trust to Initiate Clinical Trials of Its Novel Oral Therapy for Beta Cell Survival and Function
BIRMINGHAM, Ala.--(BUSINESS WIRE)--TIXiMED is developing a proprietary non-immunosuppressive therapy that may become first oral disease-modifying treatment option for type 1 diabetes.Kinexum Congratulates TIXiMED
Kinexum congratulates TIXiMED on obtaining clearance from the US FDA to commence clinical testing of its TIX100. WASHINGTON, DC, UNITED STATES, July 23, 2024 /EINPresswire.com/ -- Kinexum congratulates TIXiMED (www.tiximed.com) on obtaining clearance …
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding TIXiMED
Sign Up For FreeTo access detailed company insights
TIXiMED develops and commercializes TXNIP [tix-nip] inhibiting medication as a first-of-its-kind oral therapeutic for Type 1 and Type 2 Diabetes.... Read More
